Therapeutic options to target angiogenesis in human malignancies

Bibliography

• CARMELIET P: Mechanisms of angiogenesis and arteriogenesis. Nat. Med. (2000) 6(4):389-395.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. (1995) 1(1):27-31.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. (1971) 285(21):1182-1186.
   PubMed Web of Science ®Google Scholar
• CARMELIET P, JAIN RK: Angiogenesis in cancer and other diseases. Nature (2000) 407(6801):249-257.
   PubMed Web of Science ®Google Scholar
• ROBINSON CJ, STRINGER SE: The splice variants of VEGF (VEGF) and their receptors. J. Cell Sci. (2001) 114(Pt 5):853-865.
   PubMed Web of Science ®Google Scholar
• HIRAOKA N, ALLEN E, APEL IJ, GYETKO MR, WEISS SJ: Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell (1998) 95(3):365-377.
   PubMed Web of Science ®Google Scholar
• FERRARA N, KERBEL RS: Angiogenesis as a therapeutic target. Nature (2005) 438(7070):967-974.
   PubMed Web of Science ®Google Scholar
• DVORAK HF: Vascular permeability factor/VEGF: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. (2002) 20(21):4368-4380.
   PubMed Web of Science ®Google Scholar
• FERRARA N, DAVIS-SMYTH T: The biology of vascular endothelial growth factor. Endocr. Rev. (1997) 18(1):4-25.
   PubMed Web of Science ®Google Scholar
• YANCOPOULOS GD, DAVIS S, GALE NW et al.: Vascular-specific growth factors and blood vessel formation. Nature (2000) 407(6801):242-248.
   PubMed Web of Science ®Google Scholar
• FERRARA N: VEGF and the quest for tumour angiogenesis factors. Nat Rev. Cancer (2002) 2(10):795-803.
   PubMed Web of Science ®Google Scholar
• FERRARA N, GERBER HP, LECOUTER J: The biology of VEGF and its receptors. Nat. Med. (2003) 9(6):669-676.
   PubMed Web of Science ®Google Scholar
• SAFRAN M, KAELIN WG Jr: HIF hydroxylation and the mammalian oxygen-sensing pathway. J. Clin. Invest. (2003) 111(6):779-783.
   PubMed Web of Science ®Google Scholar
• DOR Y, PORAT R, KESHET E: VEGF and vascular adjustments to perturbations in oxygen homeostasis. Am. J. Physiol. Cell Physiol. (2001) 280(6):C1367-C1374.
   PubMed Web of Science ®Google Scholar
• MCMAHON G: VEGF receptor signaling in tumor angiogenesis. Oncologist (2000) 5(Suppl. 1):3-10.
   PubMedGoogle Scholar
• LUTTUN A, TJWA M, MOONS L et al.: Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt-1. Nat. Med. (2002) 8(8):831-840.
   PubMed Web of Science ®Google Scholar
• HATTORI K, HEISSIG B, WU Y et al.: Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment. Nat. Med. (2002) 8(8):841-849.
   PubMed Web of Science ®Google Scholar
• HIRATSUKA S, NAKAMURA K, IWAI S et al.: MMP9 induction by VEGFR-1 is involved in lung-specific metastasis. Cancer Cell (2002) 2(4):289-300.
   PubMed Web of Science ®Google Scholar
• KAPLAN RN, RIBA RD, ZACHAROULIS S et al.: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature (2005) 438(7069):820-827.
   PubMed Web of Science ®Google Scholar
• LECOUTER J, MORITZ DR, LI B et al.: Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science (2003) 299(5608):890-893.
   PubMed Web of Science ®Google Scholar
• KIM KJ, LI B, WINER J et al.: Inhibition of VEGF-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 362(6423):841-844.
   PubMed Web of Science ®Google Scholar
• MILLAUER B, SHAWVER LK, PLATE KH, RISAU W, ULLRICH A: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature (1994) 367(6463):576-579.
   PubMed Web of Science ®Google Scholar
• LIST AF: VEGF signaling pathway as an emerging target in hematologic malignancies. Oncologist (2001) 6(Suppl. 5):24-31.
   PubMed Web of Science ®Google Scholar
• LEE JC, CHOW NH, WANG ST, HUANG SM: Prognostic value of VEGF expression in colorectal cancer patients. Eur. J. Cancer (2000) 36(6):748-753.
   PubMed Web of Science ®Google Scholar
• TOKUNAGA T, OSHIKA Y, ABE Y et al.: VEGF mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br. J. Cancer (1998) 77(6):998-1002.
   PubMed Web of Science ®Google Scholar
• CREW JP, O'BRIEN T, BRADBURN M et al.: VEGF is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res. (1997) 57(23):5281-5285.
   PubMed Web of Science ®Google Scholar
• LINDERHOLM B, TAVELIN B, GRANKVIST K, HENRIKSSON R: VEGF is of high prognostic value in node-negative breast carcinoma. J. Clin. Oncol. (1998) 16(9):3121-3128.
   PubMed Web of Science ®Google Scholar
• FONTANINI G, FAVIANA P, LUCCHI M et al.: A high vascular count and overexpression of VEGF are associated with unfavourable prognosis in operated small cell lung carcinoma. Br. J. Cancer (2002) 86(4):558-563.
   PubMed Web of Science ®Google Scholar
• FUJIMOTO J, SAKAGUCHI H, AOKI I, KHATUN S, TAMAYA T: Clinical implications of expression of VEGF in metastatic lesions of ovarian cancers. Br. J. Cancer (2001) 85(3):313-316.
   PubMed Web of Science ®Google Scholar
• PALEY PJ, STASKUS KA, GEBHARD K et al.: VEGF expression in early stage ovarian carcinoma. Cancer (1997) 80(1):98-106.
   PubMed Web of Science ®Google Scholar
• EGGERT A, IKEGAKI N, KWIATKOWSKI J et al.: High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin. Cancer Res. (2000) 6(5):1900-1908.
   PubMed Web of Science ®Google Scholar
• JACOBSEN J, RASMUSON T, GRANKVIST K, LJUNGBERG B: VEGF as prognostic factor in renal cell carcinoma. J. Urol. (2000) 163(1):343-347.
   PubMed Web of Science ®Google Scholar
• SAUTER ER, NESBIT M, WATSON JC et al.: VEGF is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin. Cancer Res. (1999) 5(4):775-782.
   PubMed Web of Science ®Google Scholar
• AGUAYO A, KANTARJIAN HM, ESTEY EH et al.: Plasma VEGF levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer (2002) 95(9):1923-1930.
   PubMed Web of Science ®Google Scholar
• DIAS S, HATTORI K, ZHU Z et al.: Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J. Clin. Invest. (2000) 106(4):511-521.
   PubMed Web of Science ®Google Scholar
• KRAFT A, WEINDEL K, OCHS A et al.: VEGF in the sera and effusions of patients with malignant and nonmalignant disease. Cancer (1999) 85(1):178-187.
   PubMed Web of Science ®Google Scholar
• ZEBROWSKI BK, YANO S, LIU W et al.: VEGF levels and induction of permeability in malignant pleural effusions. Clin. Cancer Res. (1999) 5(11):3364-3368.
   PubMed Web of Science ®Google Scholar
• LUO JC, TOYODA M, SHIBUYA M: Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an anti-VEGF/permeability factor neutralizing antibody. Cancer Res. (1998) 58(12):2594-2600.
   PubMed Web of Science ®Google Scholar
• LINDAHL P, JOHANSSON BR, LEVEÉN P, BETSHOLTZ C: Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science (1997) 277(5323):242-245.
   PubMed Web of Science ®Google Scholar
• HELLSTRÖM M, KALEN M, LINDAHL P, ABRAMSSON A, BETSHOLTZ C: Role of PDGF-B and PDGFR-β in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development (1999) 126(14):3047-3055.
   PubMed Web of Science ®Google Scholar
• JECHLINGER M, SOMMER A, MORIGGL R et al.: Autocrine PDGFR signaling promotes mammary cancer metastasis. J. Clin. Invest. (2006) 116(6):1561-1570.
   PubMed Web of Science ®Google Scholar
• TAIT CR, JONES PF: Angiopoietins in tumours: the angiogenic switch. J. Pathol. (2004) 204:1-10.
   PubMed Web of Science ®Google Scholar
• OLINER J, MIN H, LEAL J et al.: Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell (2004) 6(5):507-516.
   PubMed Web of Science ®Google Scholar
• NAKAYAMA T, HATACHI G, WEN CY et al.: Expression and significance of Tie-1 and -2 receptors, and angiopoietins-1, -2 and -4 in colorectal adenocarcinoma: immunohistochemical analysis and correlation with clinicopathological factors. World J. Gastroenterol. (2005) 11(7):964-969.
   PubMed Web of Science ®Google Scholar
• HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350(23):2335-2342.
   PubMed Web of Science ®Google Scholar
• HOCHSTER H, WELLES L, HART L et al: Bevacizumab (B) with oxaliplatin (O)-based chemotherapy in the first-line therapy of metastatic colorectal cancer (mCRC): preliminary results of the randomized "TREE-2" trial. 303. Gastrointestinal Cancers Symposium (2005):241.
   Google Scholar
• YANG JC, HAWORTH L, SHERRY RM et al.: A randomized trial of bevacizumab, an anti-VEGF antibody, for metastatic renal cancer. N. Engl. J. Med. (2003) 349(5):427-434.
   PubMed Web of Science ®Google Scholar
• BUKOWSKI RM, KABBINAVAR F, FIGLIN RA et al.: Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). J. Clin. Oncol. (Meeting Abstracts) (2006) 24:4523.
   Web of Science ®Google Scholar
• RINI BI, HALABI S, TAYLOR J et al.: Cancer and Leukemia Group B 90206: A randomized Phase III trial of IFN-α or IFN-α plus anti-VEGF antibody (bevacizumab) in metastatic renal cell carcinoma. Clin. Cancer Res. (2004) 10(8):2584-2586.
   PubMed Web of Science ®Google Scholar
• HAINSWORTH JD, SOSMAN JA, SPIGEL DR et al.: Bevacizumab, erlotinib, and imatinib in the treatment of patients (pts) with advanced renal cell carcinoma (RCC): A Minnie Pearl Cancer Research Network Phase I/II trial. 272. J. Clin. Oncol. (Meeting Abstracts) (2005) 23(16 Suppl.):4542.
   Google Scholar
• JOHNSON DH, FEHRENBACHER L, NOVOTNY WF et al.: Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. (2004) 22(11):2184-2191.
   PubMed Web of Science ®Google Scholar
• SANDLER AB, GRAY R, BRAHMER J et al.: Randomized Phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial - E4599. J. Clin. Oncol. (Meeting Abstracts) (2005) 23(Suppl. 16):LBA4.
   Google Scholar
• HERBST RS, JOHNSON DH, MININBERG E et al.: Phase I/II trial evaluating the anti-VEGF monoclonal antibody bevacizumab in combination with the HER-1/EGF receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. (2005) 23(11):2544-2555.
   PubMed Web of Science ®Google Scholar
• FEHRENBACHER L, O'NEILL V, BELANI CP et al.: A Phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. J. Clin. Oncol. (Meeting Abstracts) (2006) 24(18 Suppl.):7062.
   Google Scholar
• KINDLER HL, FRIBERG G, SINGH DA et al.: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. (2005) 23(31):8033-8040.
   PubMed Web of Science ®Google Scholar
• ZHU AX, BLASZKOWSKY LS, RYAN DP et al.: Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. (2006) 24(12):1898-1903.
   PubMed Web of Science ®Google Scholar
• MILLER KD, CHAP LI, HOLMES FA et al.: Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. (2005) 23(4):792-799.
   PubMed Web of Science ®Google Scholar
• BERNSTEIN JA, SCHUBBERT T, KONG K, MEHTA RS: Weekly carboplatin and nab-paclitaxel plus trastuzumab, or plus or minus bevacizumab: Clinical response in patients with breast cancer. J. Clin. Oncol. (Meeting Abstracts) (2006) 24(18 Suppl.):10699.
   Google Scholar
• JAYSON GC, MULATERO C, RANSON M et al.: Phase I investigation of recombinant anti-human VEGF antibody in patients with advanced cancer. Eur. J. Cancer (2005) 41(4):555-563.
   PubMed Web of Science ®Google Scholar
• HOLASH J, DAVIS S, PAPADOPOULOS N et al.: VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA (2002) 99(17):11393-11398.
   PubMed Web of Science ®Google Scholar
• KIM ES, SERUR A, HUANG J et al.: Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc. Natl. Acad. Sci. USA (2002) 99(17):11399-11404.
   PubMed Web of Science ®Google Scholar
• HU L, HOFMANN J, HOLASH J et al.: VEGF trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin. Cancer Res. (2005) 11(19 Pt 1):6966-6971.
   PubMed Web of Science ®Google Scholar
• DUPONT J, SCHWARTZ L, KOUTCHER J et al.: Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies. J. Clin. Oncol. (Meeting Abstracts) (2004) 22(Suppl. 14):3009.
   Google Scholar
• HUNT S: Technology evaluation: IMC-1C11, ImClone Systems. Curr. Opin. Mol. Ther. (2001) 3(4):418-424.
   PubMed Web of Science ®Google Scholar
• POSEY JA, NG TC, YANG B et al.: A Phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin. Cancer Res. (2003) 9(4):1323-1332.
   PubMed Web of Science ®Google Scholar
• MENDEL DB, LAIRD AD, XIN X et al.: In vivo anti-tumor and mechanism of action studies of SU11248, a potent and selective inhibitor of the VEGF and PDGF receptors. Proc. Am. Assoc. Cancer Res. Annual Meeting (2002) 43:10811.
   Google Scholar
• O'FARRELL AM, ABRAMS TJ, YUEN HA et al.: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood (2003) 101(9):3597-3605.
   PubMed Web of Science ®Google Scholar
• O'FARRELL AM, FORAN JM, FIEDLER W et al.: An innovative Phase I clinical study demonstrates inhibition of Flt-3 phosphorylation by SU-11248 in acute myeloid leukemia patients. Clin. Cancer Res. (2003) 9(15):5465-5476.
   PubMed Web of Science ®Google Scholar
• CARTER TA, WODICKA LM, SHAH NP et al.: Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl. Acad. Sci. USA (2005) 102(31):11011-11016.
   PubMed Web of Science ®Google Scholar
• PRENEN H, COOLS J, MENTENS N et al.: Efficacy of the kinase inhibitor SU-11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin. Cancer Res. (2006) 12(8):2622-2627.
   PubMed Web of Science ®Google Scholar
• MOTZER RJ, MICHAELSON MD, REDMAN BG et al.: Activity of SU11248, a multitargeted inhibitor of VEGF receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. (2006) 24(1):16-24.
   PubMed Web of Science ®Google Scholar
• MOTZER RJ, HUTSON TE, TOMCZAK P et al.: Phase III randomized trial of sunitinib malate (SU11248) versus IFN-α as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. (Meeting Abstracts) (2006) 24(Suppl. 18):LBA3.
   Google Scholar
• MOTZER RJ, Rini BI, Bukowski RM et al.: Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 295:2516-2524.
   PubMed Web of Science ®Google Scholar
• CASALI PG, GARRETT CR, BLACKSTEIN ME et al.: Updated results from a Phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. J. Clin. Oncol. (Meeting Abstracts) (2006) 24(Suppl. 18):9513.
   Google Scholar
• SOCINSKI MA, NOVELLO S, SANCHEZ JM et al.: Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter Phase II trial. J. Clin. Oncol. (Meeting Abstracts) (2006) 24(Suppl. 18):7001.
   Web of Science ®Google Scholar
• RICHLY H, KUPSCH P, PASSAGE K et al.: Results of a Phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer. Int. J. Clin. Pharmacol. Ther. (2004) 42(11):650-651.
   PubMedGoogle Scholar
• RATAIN MJ, EISEN T, STADLER WM et al.: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. (2006) 24(16):2505-2512.
   PubMed Web of Science ®Google Scholar
• RATAIN MJ, EISEN T, STADLER WM et al.: Final findings from a Phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J. Clin. Oncol. (Meeting Abstracts) (2005) 23(Suppl. 16):4544.
   Google Scholar
• WOOD JM, BOLD G, BUCHDUNGER E et al.: PTK787/ZK 222584, a novel and potent inhibitor of VEGF receptor tyrosine kinases, impairs VEGF-induced responses and tumor growth after oral administration. Cancer Res (2000) 60(8):2178-2189.
   PubMed Web of Science ®Google Scholar
• HECHT JR, TRARBACH T, JAEGER E et al.: A randomized, double-blind, placebo-controlled, Phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J. Clin. Oncol. (Meeting Abstracts) (2005) 23(Suppl. 16):LBA3.
   Google Scholar
• MROSS K, DREVS J, MULLER M et al.: Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur. J. Cancer (2005) 41(9):1291-1299.
   PubMed Web of Science ®Google Scholar
• GAULER TC, FISCHER B, SORIA J et al.: Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 orally administered once daily at 1250 mg as second-line monotherapy in patients (pts) with stage IIIB or stage IV non-small cell lung cancer (NSCLC). J. Clin. Oncol. (Meeting Abstracts) (2006) 24(Suppl. 18):7195.
   Google Scholar
• JOENSUU H, DE BRAUD F, COCO P et al.: A Phase II, open-label study of PTK787/ZK222584 in the treatment of metastatic gastrointestinal stromal tumors (GISTs) resistant to imatinib mesylate. J. Clin. Oncol. (Meeting Abstracts) (2006) 24(Suppl. 18):9531.
   Google Scholar
• ANTHONY LB, CRONIN M, O'DORISIO T, O'DORISIO S: An open-label Phase II study evaluating the safety and efficacy of PTK787 in patients with progressive metastatic neuroendocrine cancer. J. Clin. Oncol. (Meeting Abstracts) (2006) 24(Suppl. 18):14124.
   Google Scholar
• HERBST R, KURZROCK R, PARSON M et al.: AMG 706 first in human, open-label, dose-finding study evaluating the safety and pharmacokinetics (PK) in subjects with advanced solid tumours. Eur. J. Cancer Suppl. (2004) 2(8):48. Abstract 151.
   Google Scholar
• ROSEN L, KURZROCK R, JACKSON E et al.: Safety and pharmacokinetics of AMG 706 in patients with advanced solid tumors. 253. J. Clin. Oncol. (Meeting Abstracts) (2005) 23(Suppl. 16):3013.
   Google Scholar
• HERBST RS, KURZOCK R, PARSON M et al.: Safety, pharmacokinetics and pharmacodynamics of AMG 706 in patients with advanced solid tumors. Eur. J. Cancer Suppl. (2005) 3(2):421 Abstract 1455.
   Google Scholar
• BOUGHTON D, ROSEN L, VAN VUGT A et al.: Safety and antitumor activity of AMG 706 in patients (pts) with thyroid cancer (TC): A subset analysis from a Phase 1 dose-finding study. J. Clin. Oncol. (Meeting Abstracts) (2006) 24(Suppl. 18.):3030.
   Google Scholar
• BLUMENSCHEIN G Jr, SANDLER A, O'ROURKE T et al.: Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/paclitaxel (CP) for the treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. (Meeting Abstracts) (2006) 24(Suppl. 18):7119.
   Google Scholar
• WEDGE SR, OGILVIE DJ, DUKES M et al.: ZD-6474 inhibits VEGF signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. (2002) 62(16):4645-4655.
   PubMed Web of Science ®Google Scholar
• CIARDIELLO F, CAPUTO R, DAMIANO V et al.: Antitumor effects of ZD-6474, a small molecule VEGF receptor tyrosine kinase inhibitor, with additional activity against EGF receptor tyrosine kinase. Clin. Cancer Res. (2003) 9(4):1546-1556.
   PubMed Web of Science ®Google Scholar
• CARLOMAGNO F, VITAGLIANO D, GUIDA T et al.: ZD-6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. (2002) 62(24):7284-7290.
   PubMed Web of Science ®Google Scholar
• MILLER KD, TRIGO JM, WHEELER C et al.: A multicenter Phase II trial of ZD6474, a VEGF receptor-2 and EGF receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin. Cancer Res. (2005) 11(9):3369-3376.
   PubMed Web of Science ®Google Scholar
• NATALE RB, BODKIN D, GOVINDAN R et al.: ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized Phase II trial. J. Clin. Oncol. (Meeting Abstracts) (2006) 24(Suppl. 18):7000.
   Google Scholar
• WELLS S, YOU YN, LAKHANI V et al.: A Phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer. J. Clin. Oncol. (Meeting Abstracts) (2006) 24(Suppl. 18):5533.
   Google Scholar
• HOLDEN SN, ECKHARDT SG, BASSER R et al.: Clinical evaluation of ZD-6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann. Oncol. (2005) 16(8):1391-1397.
   PubMed Web of Science ®Google Scholar
• HEYMACH JV, JOHNSON BE, PRAGER D et al.: A Phase II trial of ZD-6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results. J. Clin. Oncol. (Meeting Abstracts) (2006) 24(Suppl. 18):7016.
   Google Scholar
• SUTTLE AB, HURWITZ H, DOWLATI A et al: Pharmacokinetics (PK) and tolerability of GW-786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors. J. Clin. Oncol. (2004):A3054.
   Google Scholar
• BEEBE JS, JANI JP, KNAUTH E et al.: Pharmacological characterization of CP-547,632, a novel VEGF receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res. (2003) 63(21):7301-7309.
   PubMed Web of Science ®Google Scholar
• RUGO HS, HERBST RS, LIU G et al.: Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J. Clin. Oncol. (2005) 23(24):5474-5483.
   PubMed Web of Science ®Google Scholar
• RINI B, RIXE O, BUKOWSKI R et al.: AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). J. Clin. Oncol. (Meeting Abstracts) (2005)23:4509.
   PubMed Web of Science ®Google Scholar
• TRAXLER P, ALLEGRINI PR, BRANDT R et al.: AEE788: a dual family EGF receptor/ErbB2 and VEGF receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. (2004) 64(14):4931-4941.
   PubMed Web of Science ®Google Scholar
• GOUDAR RK, SHI Q, HJELMELAND MD et al.: Combination therapy of inhibitors of EGF receptor/VEGF receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol. Cancer Ther. (2005) 4(1):101-112.
   PubMed Web of Science ®Google Scholar
• YAZICI S, KIM SJ, BUSBY JE et al.: Dual inhibition of the EGF and VEGF phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice. Prostate (2005) 65(3):203-215.
   PubMed Web of Science ®Google Scholar
• RUGGERI B, SINGH J, GINGRICH D et al.: CEP-7055: a novel, orally active pan inhibitor of VEGF receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res. (2003) 63(18):5978-5991.
   PubMed Web of Science ®Google Scholar
• PAVCO PA, BOUHANA KS, GALLEGOS AM et al.: Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of VEGF receptors. Clin. Cancer Res. (2000) 6(5):2094-2103.
   PubMed Web of Science ®Google Scholar
• WENG DE, MASCI PA, RADKA SF et al.: A Phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting VEGF receptor-1 for patients with refractory solid tumors. Mol. Cancer Ther. (2005) 4(6):948-955.
   PubMed Web of Science ®Google Scholar
• SIER CF, KUBBEN FJ, GANESH S et al.: Tissue levels of matrix metalloproteinases MMP-2 and -9 are related to the overall survival of patients with gastric carcinoma. Br. J. Cancer (1996) 74(3):413-417.
   PubMed Web of Science ®Google Scholar
• NOMURA H, SATO H, SEIKI M, MAI M, OKADA Y: Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res. (1995) 55(15):3263-3266.
   PubMed Web of Science ®Google Scholar
• DEZUBE BJ, KROWN SE, LEE JY, BAUER KS, ABOULAFIA DM: Randomized Phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. J. Clin. Oncol. (2006) 24(9):1389-1394.
   PubMed Web of Science ®Google Scholar
• RIZVI NA, HUMPHREY JS, NESS EA et al.: A Phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin. Cancer Res. (2004) 10(6):1963-1970.
   PubMed Web of Science ®Google Scholar
• LARA PN, JR., STADLER WM, LONGMATE J et al.: A randomized Phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin. Cancer Res. (2006) 12(5):1556-1563.
   PubMed Web of Science ®Google Scholar
• HOEKSTRA R, DE VOS FY, ESKENS FA et al.: Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J. Clin. Oncol. (2005) 23(22):5188-5197.
   PubMed Web of Science ®Google Scholar
• NIKOLOPOULOS SN, BLAIKIE P, YOSHIOKA T, GUO W, GIANCOTTI FG: Integrin-4 signaling promotes tumor angiogenesis. Cancer Cell (2004) 6(5):471-483.
   PubMed Web of Science ®Google Scholar
• TEO SK: Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS. J. (2005) 7(1):E14-E19.
   PubMed Web of Science ®Google Scholar
• ABDOLLAHI A, HLATKY L, HUBER PE: Endostatin: the logic of antiangiogenic therapy. Drug Resist. Updat. (2005) 8(1-2):59-74.
   PubMed Web of Science ®Google Scholar
• HERBST RS, HESS KR, TRAN HT et al.: Phase I study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. (2002) 20(18):3792-3803.
   PubMed Web of Science ®Google Scholar
• GANTI AK, POTTI A: Epidermal growth factor inhibition in solid tumours. Expert Opin. Biol.Ther. (2005) 5(9):1165-1174.
   PubMed Web of Science ®Google Scholar
• JAIN RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 307(5706):58-62.
   PubMed Web of Science ®Google Scholar
• BROWDER T, BUTTERFIELD CE, KRÄLING BM et al.: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. (2000) 60(7):1878-1886.
   PubMed Web of Science ®Google Scholar
• KLEMENT G, BARUCHEL S, RAK J et al.: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. (2000) 105(8):R15-R24.
   PubMed Web of Science ®Google Scholar
• SALTZ LB, LENZ HJ, HOCHSTER H et al.: Randomized Phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. 259. J. Clin. Oncol. (Meeting Abstracts) (2005) 23(Suppl. 16):3508.
   Google Scholar
• DAVIS DW, MCCONKEY DJ, ABBRUZZESE JL, HERBST RS: Surrogate markets in antiangiogenesis clinical trials. Br. J. Cancer (2003) 89(1):8-14.
   PubMed Web of Science ®Google Scholar
• FANELLI M, LOCOPO N, GATTUSO D, GASPARINI G: Assessment of tumor vascularization: immunohistochemical and non-invasive methods. Int. J. Biol. Markers (1999) 14(4):218-231.
   PubMed Web of Science ®Google Scholar
• VERMEULEN PB, GASPARINI G, FOX SB et al.: Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur. J. Cancer (1996) 32A(14):2474-2484.
   PubMed Web of Science ®Google Scholar
• MORGAN B, THOMAS AL, DREVS J et al.: Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the VEGF receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two Phase I studies. J. Clin. Oncol. (2003) 21(21):3955-3964.
   PubMed Web of Science ®Google Scholar
• YU JL, RAK JW, COOMBER BL, HICKLIN DJ, KERBEL RS: Effect of p53 status on tumor response to antiangiogenic therapy. Science (2002) 295(5559):1526-1528.
   PubMed Web of Science ®Google Scholar
• STREUBEL B, CHOTT A, HUBER D et al.: Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N. Engl. J. Med. (2004) 351(3):250-259.
   PubMed Web of Science ®Google Scholar
• WEDGE SR, KENDREW J, HENNEQUIN LF et al.: AZD-2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. (2005) 65(10):4389-4400.
   PubMed Web of Science ®Google Scholar
• WILHELM SM, CARTER C, TANG L et al.: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/EREK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. (2004) 64(19):7099-7109.
   PubMed Web of Science ®Google Scholar
• MENDEL DB, LAIRD AD, XIN X et al.: In vivo antitumor activity of SU-11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. (2003) 9(1):327-337.
   PubMed Web of Science ®Google Scholar
• DAVIS DW, MCCONKEY DJ, ABBRUZZESE JL, HERBST RS: Surrogate markers in antiangiogenesis clinical trials. Br. J. Cancer (2003) 89:8-14
   PubMed Web of Science ®Google Scholar